Categories: Wire Stories

HighField Biopharmaceuticals’ HF1K16, a New Immuno-Oncology Drug, Shows Promise in Patients with Refractory Glioblastoma

The abstract of preliminary data from a Phase 1a trial of HF1K16, which targets myeloid-derived suppressor cells (MDSCs), is published online at the 2023 ASCO Annual Meeting in Chicago, IL

HANGZHOU, China–(BUSINESS WIRE)–HighField Biopharmaceuticals (HighField Bio), a clinical stage immuno-oncology company using immunoliposomes to treat cancer, announced today the publication of an abstract including preliminary data from a Phase 1a clinical trial of HF1K16 in refractory metastatic cancer patients. It was published online at the American Society of Clinical Oncology (ASCO) Annual Meeting. HF1K16 is a drug encapsulated immune modulating liposome containing all-trans retinoic acid. The ASCO meeting is June 2 – 6, 2023, at the McCormick Place, Chicago, IL.

The HighField Bio abstract is titled “Modulating MDSCs by HF1K16: a monotherapy Phase 1a study examining safety and preliminary efficacy in refractory and metastatic cancer patients.”

“We are excited about the preliminary data,” said Yuhong Xu, CEO of HighField Bio. “The data show HF1K16 is well tolerated and patients have experienced significant progression-free survival.” The abstract also reports that of the 11 patients treated, three who suffer from recurrent and refractory glioma continued to experience progression-free survival. One patient has been on treatment for 348 days. The other two are 94 days and 52 days with progression-free survival from the start of treatment.

Dr. Xu noted, “Four patients reached stable disease diagnosis based on RECIST 1.1 criteria. One patient experienced a reduction in size of the main brain lesion from 70mm to 23.7mm.”

HF1K16 is a unique liposome construct of ATRA, a small molecule metabolite of vitamin A, administered by infusion, and travels through the blood stream and infiltrates the tumor microenvironment. ATRA is released and initiates the maturation of Myeloid-Derived Suppressor Cells (MDSCs).

MDSCs are immature myeloid cells which have not differentiated. ATRA promotes the maturation and differentiation of MDSCs into functional cells, such as dendritic cells, which then summon T cells to attack the cancer.

The preliminary data reported at ASCO is from an ongoing Phase 1a trial in China with patients suffering from a variety of refractory metastatic cancers. Based on the positive findings related to glioma, HighField Bio expects to begin a Phase 1b/2 trial in China for patients with refractory glioma in the next few weeks.

About HighField Biopharmaceuticals

HighField Bio is a clinical stage immuno-oncology company focused on novel applications of liposome constructs to disrupt existing immuno-oncology technologies. The company has a research and development center and a GMP-compliant production facility. HighField Bio’s lead clinical development program is HF1K16, a drug encapsulated immune modulating liposome containing all-trans retinoic acid targeting myeloid-derived suppressor cells for treatment of solid tumors. For more information visit https://highfield.bio.

Contacts

Media Contact:

Dan Eramian

Opus Biotech Communications

danieleramian@comcast.net
425-306-8716

Business Development Contact:

Donald Wyatt

HighField Biopharmaceuticals

dwyatt@hf-biopharm.com
206-356-8196

Alex

Recent Posts

CGTN: China vows continued efforts to build Asia-Pacific community with shared future

BEIJING, CHINA - Media OutReach Newswire - 8 November 2024 - Since its inception more…

1 hour ago

TBS Energi Utama to Acquire Singapore’s Integrated Waste Management Services Provider, Sembcorp Environment Pte. Ltd.

Acquisition Expands TBS’ Regional Waste Management Platform in Indonesia and Singapore, aligning with its TBS2030…

3 hours ago

Score 11 Unbeatable Deals This 11.11 on Shopee with 90% Off Lowest Price Guaranteed

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 8 November 2024 - It’s that time…

5 hours ago

Shenzhen China Wins the World Smart City Award, Demonstrating the Global Influence of Social Intelligent Governance of Mega City

BARCELONA, SPAIN - Media OutReach Newswire - 8 November 2024 - On November 6, Central…

6 hours ago

Singapore – A Trusted Global Supply Chain Management Hub

SINGAPORE - Media OutReach Newswire - 8 November 2024 - Singapore is strengthening its position…

7 hours ago

OPPO Celebrates Global Photography Talent at Paris Photo Fair under the theme of “Dear Life”

PARIS, FRANCE - Media OutReach Newswire – 8 November 2024 - This year, OPPO once…

8 hours ago